| Drug Name |
Cimetidine hydrochloride |
| Drug ID |
BADD_D00468 |
| Description |
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. |
| Indications and Usage |
Cimetidine is indicated to reduce gastric acid secretion and to treat the following disease states: duodenal ulcers, non-malignant gastric ulcers, gastroesophageal reflux disease, and pathological hypersecretion associated with Zollinger-Ellison Syndrome, systemic mastocytosis, and multiple endocrine adenomas.[L30280] It is indicated for prophylaxis of recurrent gastric or duodenal ulcers, as adjunctive therapy in the management of cystic fibrosis in children, and to treat NSAID induced lesions and gastrointestinal symptoms.[L30280] |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB00501
|
| KEGG ID |
D03503
|
| MeSH ID |
D002927
|
| PubChem ID |
50963
|
| TTD Drug ID |
D02DPA
|
| NDC Product Code |
0121-1298; 50383-966; 49964-0019; 0121-0649 |
| UNII |
WF10491673
|
| Synonyms |
Cimetidine | N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine | Biomet | Biomet400 | Cimetidine Hydrochloride | Hydrochloride, Cimetidine | Cimetidine HCl | HCl, Cimetidine | Histodil | SK&F-92334 | SK&F 92334 | SK&F92334 | SKF-92334 | SKF 92334 | SKF92334 | Tagamet | Altramet | Eureceptor |
